Seroxat, the anti-depressant that had been linked to heart abnormalities, is apparently safe to use in pregnant women, German researchers told a European fertility conference yesterday. The researchers said that they found no increased risk and that women might have unnecessarily terminated their pregnancies fearing that the drug could affect their babies.
Researchers at the University of Ulm studied 119 women treated with Seroxat for six years between 1999 and 2005. They then compared the pregnancies of these women with 645 women who did not use the drug.
Advertisement
Only three abnormalities were reported with the use of the drug, namely, clubfeet, a large port wine mark and neck muscle spasms. However in the group, which did not use the drug, 25 out of 557 babies were affected. But in the Seroxat group 15 percent decided to terminate their pregnancy as against 17 out of 557 in the non-drug group.
"We found that the rate of congenital abnormalities was not increased after using paroxetine in early pregnancy. Women and their physicians should discuss this information and make an informed decision, whether or not to continue with paroxetine during pregnancy," said lead researcher Dr Wolfgang Paulus, director of the Institute of Reproductive Toxicology at the University of Ulm.
"Concerned patients can be offered ultrasound and echocardiogram, which can rule out fetal cardiac problems in early pregnancy. Antidepressants should never be stopped abruptly as this can have serious ramifications for the mother," he added.
"Concerned patients can be offered ultrasound and echocardiogram, which can rule out fetal cardiac problems in early pregnancy. Antidepressants should never be stopped abruptly as this can have serious ramifications for the mother," he added.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.